- COMPOUND SERVING AS IRAK INHIBITOR
-
The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.
- -
-
Paragraph 0153-0154; 0212-0213; 0255-0256
(2021/10/07)
-
- 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
-
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
- -
-
Page/Page column 90-91; 92; 73
(2021/04/17)
-
- SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS
-
The present invention provides compounds of Formula (I): useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
- -
-
Paragraph 00190
(2020/03/02)
-
- DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
-
Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.
- -
-
Page/Page column 54
(2019/11/28)
-
- Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions
-
Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.
- Tissot, Matthieu,Body, Nathalie,Petit, Sylvain,Claessens, Jehan,Genicot, Christophe,Pasau, Patrick
-
supporting information
p. 8022 - 8025
(2019/01/04)
-
- SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF
-
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1) - mediated diseases or disorders, Formula (I), wherein R1, R2, R3, R4, and R5 are as defined herein.
- -
-
Paragraph 00274; 00348
(2019/01/10)
-
- N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS
-
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
- -
-
Page/Page column 65
(2008/06/13)
-